Sarsia Seed leads Avexxin funding round

The funding round was made in syndication with Leiv Eiriksson Invest. Financing will be used to support Avexxin's lead compound against psoriasis through early clinical development.

The company was established in March 2005 and Sarsia Seed, together with Karolinska Innovation, became shareholders in the company in 2007.

The unquote" team is currently researching this transaction. In-depth deal information for subscribers will follow shortly.

If you have any information regarding this transaction, please contact Viktor Lundvall on +44 20 7004 7476 or viktor.lundvall@incisivemedia.com

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Nordics
• Healthcare
• Early-stage
• Norway